Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to conduct an intervention program aimed at increasing HPV self-sampling among women living with HIV in Ghana.
Women living with HIV, (WLWH), in low- and middle-income countries (LMICs) have a six-fold increased risk of developing cervical cancer (CC) compared to their uninfected counterparts. Our studies in Ghana show that self-sampling is acceptable, easy to use, and efficacious in detecting precancer lesions among WLWH. However, this screening mechanism has not been translated to healthcare practice in Ghana.
Systematic adaptation and implementation toolkits are needed to translate self-sampling into healthcare practices. We develop a Home-based self-collected sampling for the cervical cancer Prevention Education (HOPE) toolkits to promote cervical cancer screening in Ghana. HOPE toolkit core components such as (a) self-sample HPV testing kits and (b) the 3R (Reframe, Reprioritize, and Reform) communication model will not change as they are evidence-based. The content and the intervention delivery modalities of HOPE will go through the cultural adaptation iterative processes.
This R21 resubmission seeks to develop contextually appropriate adaptation and implementation toolkits in Ghana. A three-step approach will be used for the adaption process and evaluation of the toolkit. First, we will organize focus group discussions (FGDs) to identify contextual factors affecting the toolkit adaptation and nominal group techniques (NGTs) to determine the different compositions of the toolkits and select the final toolkit. A sample of 35 stakeholder advisory board members representing three organizational levels: potential intervention participants (i.e., WLWH), community leaders, and healthcare workers (e.g., doctors, nurses, administrators) will participate in the focus group FGDs and NGTs. Second, we will recruit 45 participants including WLWH and healthcare workers to evaluate the feasibility, acceptability, appropriateness, and adoptability of the selected toolkit. Third, we will test the preliminary efficacy of HOPE on cervical cancer screening defined as cervical cancer screening uptake among WLWH in the intervention arm (n=54) and control arm (n = 54). Participants will be recruited from the Cape Coast Teaching Hospital (CCTH). Specific aims of HOPE are:
Aim I: Develop and adapt the HOPE toolkit: Hypothesis: Stakeholders will identify and prioritize community needs and translate findings into a culturally adapted toolkit. Aim II: Evaluate the characteristics of the HOPE toolkit: Hypothesis: We hypothesize that 80% of participants will find HOPE toolkits feasible, acceptable, appropriate, and adoptable. Aim III: Assess the efficacy of HOPE on CCS. Hypothesis: We hypothesize that CCS behavior will increase significantly among women in the intervention group compared to those in the control group. Aim IV: Identify actionable factors and implementation costs that influence the adoption of the toolkit. Hypothesis: The Actionable factors and implementation costs will significantly influence the toolkit adoption.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HPV Self sampling | Experimental | Participants in the intervention group will receive HPV self sampling and behavioral intervention |
|
| Control Group | No Intervention | Participants in the control group will receive enhance standard care |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| HPV Self-Sampling and Behavior Intervention | Behavioral | Participants in the intervention group will receive HPV self sampling and behavioral intervention |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cervical cancer screening uptake | The outcome is screening uptake (i.e., the completion and return of a self-sample kit and pap test completion). Measure: The screening completion outcome will be binary (yes/no), and it will be assessed via the patient clinical records by the doctors at 6 weeks post-intervention. The screening completion outcome will be binary (yes/no) | 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Screening Test Results | Screening test results (positive, negative, or inadequate). Measure: The screening test results (positive, negative, or inadequate), will be treated as categorical outcome and it will be assessed via the patient clinical records by the doctors at 6 weeks post-intervention. | 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Actionable outcome : Implementation experience | Implementation experience, including resource availability, managerial support, and technical issues confronted. Measure: Following the completion of the intervention(i.e., after 6 weeks), interviews will be conducted among healthcare providers using a semi-structured interview guide to assess the implementation experience outcome. | 6 weeks after the intervention |
Inclusion Criteria:
General eligibility criteria for these stakeholders include (1) the ability to give consent per Institutional Review Board stipulations, (2) residing in the central region of Ghana, (3) having no medical, psychological, or social characteristics that would interfere with the ability to fully participate, and (4) the willingness to participate in this study.
Exclusion Criteria:
Identified female at birth
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Matthew Asare, PhD | Baylor University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Cape Coast Teaching Hospital | Cape Coast | Central Region | Ghana |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41475829 | Derived | Asare M, Ebu Enyan NI, Sencherey VL, Lamptey-Mills E, Ken-Amoah S, Akakpo PK, Sturdivant RX, Obiri-Yeboah D. Culturally adapting and evaluating an evidence-based communication intervention with HPV self-sampling to improve cervical cancer screening among women living with HIV in Ghana: a mixed-methods study. BMJ Open. 2025 Dec 31;15(12):e105852. doi: 10.1136/bmjopen-2025-105852. | |
| 41299750 | Derived | Asare M, Obiri-Yeboah D, Ken-Amoah S, Akakpo PK, Enyan NIE, Asmah E, Sturdivant RX. HPV self-sampling for cervical cancer screening among women living with HIV in Ghana: protocol for a hybrid type 1 effectiveness-implementation randomized controlled trial. Trials. 2025 Nov 26;26(1):550. doi: 10.1186/s13063-025-09262-2. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001521 | Behavior Therapy |
| ID | Term |
|---|---|
| D011613 | Psychotherapy |
| D004191 | Behavioral Disciplines and Activities |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Participants in the intervention group will receive HPV self sampling and behavioral intervention | Behavioral | Received enhance standard care |
|
| Treatment follow-up |
Whether patients with positive results follow up for treatment or not. Measures: The outcomes will be assessed via the patient clinical records by the doctors at 6 weeks post-intervention. The treatment follow-up (yes, no, or lost-to-follow-up) will be treated as categorical outcomes |
| 6 weeks |
| Actionable factor: Operational experience | Operational experience, including workload increase or decrease, the flow of communication in the hospital, and any skills needed. Measure: Following the completion of the intervention(i.e., after 6 weeks), interviews will be conducted among healthcare providers using a semi-structured interview guide to assess the operational experience outcome. | 6 weeks after the intervention |
| Actionable factor: Adoption or level of endorsement | Level of endorsement of the toolkit adoption and recommendations for maintenance. Measure: Following the completion of the intervention(i.e., after 6 weeks), interviews will be conducted among healthcare providers using a semi-structured interview guide to assess the adoption or endorsement outcome. | 6 weeks after the intervention |
| Implementation cost | Implementation costs will include (i) sampling materials, including kits and laboratory testing costs; (ii) recruitment (i.e., time spent identifying and contacting eligible women, advertising materials, participant incentives); (iii) intervention delivery; (iv) participant out-of-pocket costs (e.g., transportation, childcare, mobile data usage, time spent on the intervention); (v) clinic-based Pap tests; and (vi) treatment and biopsies. Measure: A cost-tracking database will be used throughout the study to itemize, quantify, and value the resources. | Throughout the intervention period (about 12 months) |